CN Patent

CN1608133A — 双链核糖核酸用于治疗正(+)链rna病毒感染的用途

Assigned to Alnylam Europe AG · Expires 2005-04-20 · 21y expired

What this patent protects

本发明涉及利用双链核糖核酸(dsRNA)治疗正(+)链RNA病毒感染的用途，其中dsRNA的S1链具有至少部分与病毒基因组的可翻译区的区段互补的区域。

USPTO Abstract

本发明涉及利用双链核糖核酸(dsRNA)治疗正(+)链RNA病毒感染的用途，其中dsRNA的S1链具有至少部分与病毒基因组的可翻译区的区段互补的区域。

Drugs covered by this patent

Patent Metadata

Patent number
CN1608133A
Jurisdiction
CN
Classification
—
Expires
2005-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Europe AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.